| Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment KV Myers, SR Amend, KJ Pienta Molecular cancer 18 (1), 94, 2019 | 343 | 2019 |
| Murine hind limb long bone dissection and bone marrow isolation SR Amend, KC Valkenburg, KJ Pienta Journal of visualized experiments: JoVE, 2016 | 309 | 2016 |
| Integrins and bone metastasis: integrating tumor cell and stromal cell interactions JG Schneider, SR Amend, KN Weilbaecher Bone 48 (1), 54-65, 2011 | 201 | 2011 |
| Updating the definition of cancer JS Brown, SR Amend, RH Austin, RA Gatenby, EU Hammarlund, ... Molecular Cancer Research 21 (11), 1142-1147, 2023 | 189 | 2023 |
| Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance SR Amend, G Torga, KC Lin, LG Kostecka, A de Marzo, RH Austin, ... The Prostate 79 (13), 1489-1497, 2019 | 160 | 2019 |
| Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium L Dong, RC Zieren, K Horie, CJ Kim, E Mallick, Y Jing, M Feng, ... Journal of extracellular vesicles 10 (2), e12044, 2020 | 158 | 2020 |
| Revisiting seed and soil: examining the primary tumor and cancer cell foraging in metastasis AE De Groot, S Roy, JS Brown, KJ Pienta, SR Amend Molecular Cancer Research 15 (4), 361-370, 2017 | 110 | 2017 |
| Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype SR Amend, KJ Pienta Oncotarget 6 (12), 9669, 2015 | 109 | 2015 |
| Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells KJ Pienta, EU Hammarlund, JS Brown, SR Amend, RM Axelrod Proceedings of the National Academy of Sciences 118 (7), e2020838118, 2021 | 89 | 2021 |
| Identifying key questions in the ecology and evolution of cancer AM Dujon, A Aktipis, C Alix‐Panabières, SR Amend, AM Boddy, JS Brown, ... Evolutionary Applications 14 (4), 877-892, 2021 | 79 | 2021 |
| Convergent evolution, evolving evolvability, and the origins of lethal cancer KJ Pienta, EU Hammarlund, R Axelrod, SR Amend, JS Brown Molecular Cancer Research 18 (6), 801-810, 2020 | 77 | 2020 |
| Antagonizing integrin β3 increases immunosuppression in cancer X Su, AK Esser, SR Amend, J Xiang, Y Xu, MH Ross, GC Fox, ... Cancer research 76 (12), 3484-3495, 2016 | 77 | 2016 |
| Poly‐aneuploid cancer cells promote evolvability, generating lethal cancer KJ Pienta, EU Hammarlund, R Axelrod, JS Brown, SR Amend Evolutionary Applications 13 (7), 1626-1634, 2020 | 67 | 2020 |
| Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy KJ Pienta, EU Hammarlund, RH Austin, R Axelrod, JS Brown, SR Amend Seminars in cancer biology 81, 145-159, 2022 | 64 | 2022 |
| CXCR4 protein epitope mimetic antagonist POL5551 disrupts metastasis and enhances chemotherapy effect in triple-negative breast cancer J Xiang, MA Hurchla, F Fontana, X Su, SR Amend, AK Esser, GJ Douglas, ... Molecular cancer therapeutics 14 (11), 2473-2485, 2015 | 63 | 2015 |
| Interplay between cell death and cell proliferation reveals new strategies for cancer therapy LV Loftus, SR Amend, KJ Pienta International journal of molecular sciences 23 (9), 4723, 2022 | 61 | 2022 |
| Thrombospondin‐1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts SR Amend, O Uluckan, M Hurchla, D Leib, D Veis Novack, M Silva, ... Journal of Bone and Mineral Research 30 (1), 106-115, 2015 | 60 | 2015 |
| ROS-induced cell cycle arrest as a mechanism of resistance in polyaneuploid cancer cells (PACCs) MD Kuczler, AM Olseen, KJ Pienta, SR Amend Progress in biophysics and molecular biology 165, 3-7, 2021 | 52 | 2021 |
| Ecological paradigms to understand the dynamics of metastasis SR Amend, S Roy, JS Brown, KJ Pienta Cancer letters 380 (1), 237-242, 2016 | 51 | 2016 |
| AXL is a putative tumor suppressor and dormancy regulator in prostate cancer HD Axelrod, KC Valkenburg, SR Amend, JL Hicks, P Parsana, G Torga, ... Molecular Cancer Research 17 (2), 356-369, 2019 | 50 | 2019 |
Kenneth PientaProfessor of Urology, Oncology, Pharmacology and Molecular Sciences, Johns Hopkins UniversityVerified email at jhmi.edu
